Key facts
- It has raised $340K across 1 recorded rounds; the latest was Seed Round ($340K) in Jan 2024.
- Revi Life Sciences has filed 2 Form Ds with the SEC, most recently Apr 2025 ($340K sold to 9 investors).
- Status: Out of Business.
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Revi Life Sciences
Funding rounds
1 roundsAbout Revi Life Sciences
Provider of biomedical research services intended to facilitate drug discovery and development. The company offers contract screening services utilizing standardized complex in vitro models of various human tissues, providing researchers with a predictive platform for drug testing.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2023
- Employees
- 6
- Website
- revilifesciences.com/
- Ownership
- Out of Business
Revi Life Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Revi Life Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Revi Life Sciences in its N-PORT filings yet. We sweep new filings monthly.